Materials and methods for the control of biofilm

A technology of biofilm and composition, applied in the direction of unknown raw materials, cosmetic preparations, medical preparations containing active ingredients, etc., can solve the problems of destroying innate immune homeostasis and failure to restore normal physiology

Inactive Publication Date: 2019-10-25
NOVATION COMPANIES
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Not only do these treatments fail to restore normal physiology, they also disrupt the homeostasis of innate immunity—antibiotics breed increasingly resistant bacteria, surgery or debridement causes anatomical trauma that creates another potential site of infection, topical antiseptics may Promotes the development and growth of pathogenic biofilms by eradicating normal commensals and pathogens

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Materials and methods for the control of biofilm
  • Materials and methods for the control of biofilm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0168] Example 1 - Surgical Application

[0169] In one embodiment of the invention, a sterile anti-biofilm composition is applied to a surgical site to prevent biofilm formation or to treat biofilm-associated infections at the surgical site. Surgical sites may include, for example, joint replacement, abdominal surgery, brain surgery, and oral / periodontal surgery sites.

[0170] Biofilm-associated infections that develop at surgical sites are referred to herein as "surgical site infections" or "SSIs." Surgical sites are at risk of developing SSIs due to, for example, improperly handled surgical instruments or airborne infectious agents from the operating room. SSI can be treated by administering antibiotics to the patient; however, a second surgery is usually required to treat SSI. Other procedures to treat SSI are undesirable for several reasons, eg, repeated surgical trauma to the patient, risk of recurrent infection, inadequate healing of the surgical site, and additional...

Embodiment 2

[0176] Example 2 - Intravascular Administration

[0177] In another embodiment of the invention, the anti-biofilm composition can be administered to the blood of a subject by intravascular injection.

[0178] Preferably, the injection is intravenous. The anti-biofilm composition may be a normal aqueous solution, an isotonic solution or other saline solution containing chlorhexidine.

[0179] In certain embodiments of the invention, the isotonic solution containing chlorhexidine is freshly prepared prior to administration to the subject. For example, within less than 1 minute, less than 2 minutes, about 1 minute to about 30 minutes, about 5 minutes to about 20 minutes, about 10 minutes to about 15 minutes, or any other permutation of these time periods prior to intravascular injection An isotonic solution containing the active agent is prepared.

[0180] In certain embodiments, an isotonic solution containing chlorhexidine is prepared by mixing saline solution and chlorhexid...

Embodiment 3

[0181] Example 3 - Urogenital Applications

[0182] In another embodiment of the invention, the sterile anti-biofilm composition may be administered to the urogenital tract of a subject by urogenital irrigation.

[0183] A urogenital irrigation system is a device used to irrigate one or more organs of the urogenital tract. Non-limiting examples of urogenital irrigation systems include bladder irrigation systems and urethral irrigation systems.

[0184] The sterile disinfectant solution for urogenital irrigation may be, for example, a plain aqueous solution of the active agent or an isotonic solution of the active agent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Materials and methods for preventing, inhibiting, or reducing biofilm formation and biofilm infection in a subject are provided. The materials and methods use chlorhexidine, which has been found to beaccidentally non-toxic. The lack of toxicity facilitates the use of chlorhexidine if previously considered impossible.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Application 62 / 413,116, filed October 26, 2016, which is hereby incorporated by reference in its entirety. Background technique [0003] Previous understanding of germ theory directed bacterial handling to bacteria in a free-floating (planktonic) state. Antibiotics, the main tool in the treatment of infections, are based on the kill efficiency of microorganisms studied in the free-floating (planktonic) state, acting as individual cells. Quantification of antibiotic efficacy is performed, for example, in conventional minimum inhibitory concentration (MIC) assays. However, some human (and other animal) infections are now thought to be due to the coordinated holistic behavior of entire microbial communities. These colonies often consist of microorganisms working together in a biofilm state. One component of the biofilm surrounds and protects the entire colony from attack...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/155A61K9/00A61K9/06A61K9/50A61K9/51
CPCA61K45/06A61K9/06A61K31/155A61K9/0014A61K9/0019A61K9/0034A61K9/0043A61K9/0048A61K9/007A61K9/0085A61K9/08A61L2/0088A61L2/18A61L17/005A61L2202/22A61L2300/202A61L2300/404A61K8/42A61Q11/00A61P27/02A61P29/00A61P31/04A61P35/00A61K9/0073A61K9/50A61K9/51A61K9/107A61K35/741
Inventor 卡洛琳·L·托米加雷思·克拉克塞缪尔·扎伊德斯派尔
Owner NOVATION COMPANIES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap